Phagocytosis Does Not Play a Major Role in Naturally Acquired Transmission-Blocking Immunity to Plasmodium falciparum Malaria
AUTOR(ES)
Healer, J.
FONTE
American Society for Microbiology
RESUMO
Phagocytosis of Plasmodium falciparum sexual stages in vitro and within the mosquito midgut was assayed in order to assess its role in transmission-blocking immunity to malaria. Both monocytes/macrophages (MM) and polymorphonuclear neutrophils (PMN) phagocytosed malarial gametes in vitro, but levels of phagocytosis were low. Intraerythrocytic gametocytes were not susceptible to phagocytosis. In vitro phagocytosis was positively correlated with levels of antibodies against the gamete surface proteins Pfs230 and Pfs48/45. Immunoglobulin G (IgG) subclass analysis revealed that phagocytosis was correlated with levels of antigamete IgG1. In vivo membrane-feeding experiments were performed in the presence of both pooled and individual malaria immune sera. The phagocytic process proceeded less efficiently in vivo than in vitro, which may be related to the lower ambient temperature (26°C, compared with 37°C). Finally, although we found a correlation between the ability of a serum to promote phagocytosis in vitro and the presence of antibodies against transmission-blocking target antigens, we were unable to demonstrate a role for MM- or PMN-mediated phagocytosis in reduction of infectivity of the malarial parasite to mosquitoes.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=115975Documentos Relacionados
- Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans.
- Identification of a continuous and cross-reacting epitope for Plasmodium falciparum transmission-blocking immunity.
- Effects of transmission-blocking monoclonal antibodies on different isolates of Plasmodium falciparum.
- Understanding Naturally Acquired Immunity to Plasmodium falciparum Malaria
- Two apparently nonrepeated epitopes on gametes of Plasmodium falciparum are targets of transmission-blocking antibodies.